Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Adolescent Depression and Anxiety Disorders
NCT02579928Phase 4Completed
- Sponsor
- Yale University
- Start
- Oct 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ketamine in major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Yale University. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 1 day and Multimodal Anxiety Scale for Children acute physical symptoms subscale at 1 day. Started Oct 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT02579928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579928.